Naslov: | Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer : an observational study |
---|
Avtorji: | ID Hochmair, Maximilian J (Avtor) ID Morabito, Alessandro (Avtor) ID Hao, Desiree (Avtor) ID Yang, Cheng-Ta (Avtor) ID Soo, Ross A (Avtor) ID Yang, James C-H (Avtor) ID Gucalp, Rasim (Avtor) ID Halmos, Balazs (Avtor) ID Wang, Lara (Avtor) ID Golembesky, Amanda (Avtor) ID Märten, Angela (Avtor) ID Čufer, Tanja, Klinika Golnik, Medicinska fakulteta UL (Avtor) |
Datoteke: | PDF - Predstavitvena datoteka, prenos (2,39 MB) MD5: 3F2D8BA9D4F2488B02256DB856ABFA69
URL - Izvorni URL, za dostop obiščite https://www.futuremedicine.com/doi/full/10.2217/fon-2018-0711?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed#
|
---|
Jezik: | Angleški jezik |
---|
Tipologija: | 1.01 - Izvirni znanstveni članek |
---|
Organizacija: | UKPBAG - Univerzitetna klinika za pljučne bolezni in alergijo Golnik
|
---|
Povzetek: | Aim: To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting. Materials & methods: In this retrospective, observational, multicenter study, patients (n = 204) had T790M-positive disease following first-line afatinib and started osimertinib treatment [>/=]10 months prior to data entry. Primary outcome was time on treatment. Results: Overall median time on treatment was 27.6 months (90% CI: 25.9-31.3), 30.3 months (90% CI: 27.6-44.5) in Del19-positive patients and 46.7 months (90% CI: 26.8-not reached) in Asians. The 2-year overall survival was 78.9%. Conclusion: In real-world clinical practice, sequential afatinib and osimertinib facilitates prolonged, chemotherapy-free treatment in patients with T790M acquired resistance, and is a potentially attractive strategy, especially for Del19-positive tumors. |
---|
Ključne besede: | lung neoplasms -- therapy, non-small-cell lung cancer, afatinib, osimertinib, epidermal growth factor receptor, EGFR, observational study |
---|
Status publikacije: | Objavljeno |
---|
Verzija publikacije: | Objavljena publikacija |
---|
Kraj izida: | Velika Britanija |
---|
Založnik: | Future Medicine Ltd |
---|
Leto izida: | 2018 |
---|
Št. strani: | str. 2861-2874 |
---|
Številčenje: | Vol. 14, no. 27 |
---|
PID: | 20.500.12556/DiRROS-12623 ![Povezava se odpre v novem oknu Novo okno](teme/dirros/img/NovoOkno.png) |
---|
UDK: | 616-006 |
---|
ISSN pri članku: | 1744-8301 |
---|
DOI: | 10.2217/fon-2018-0711 ![Povezava se odpre v novem oknu Novo okno](teme/dirros/img/NovoOkno.png) |
---|
COBISS.SI-ID: | 2048432753 ![Povezava se odpre v novem oknu Novo okno](teme/dirros/img/NovoOkno.png) |
---|
Avtorske pravice: | 2018 Maximilian Hochmair |
---|
Opomba: | Soavtorji: Alessandro Morabito, Desiree Hao, Cheng-Ta Yang, Ross A Soo, James C-H Yang, Rasim Gucalp, Balazs Halmos, Lara Wang, Amanda Golembesky, Angela Märten & Tanja Cufer;
Nasl. z nasl. zaslona;
Opis vira z dne 9. 1. 2019;
|
---|
Datum objave v DiRROS: | 09.11.2020 |
---|
Število ogledov: | 1649 |
---|
Število prenosov: | 991 |
---|
Metapodatki: | ![Izvoz v DC-RDF DC-RDF](teme/dirros/img/icon_dc_rdf.gif) |
---|
:
|
Kopiraj citat |
---|
| | | Objavi na: | ![Bookmark and Share](teme/dirros/img/addtoany.png) |
---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |